Investor Recommends Celera Spin Out Merck Royalty Asset

An institutional investor has suggested that the firm spin out or distribute a royalty asset tied to a Merck phase III drug.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.